Defining the Impact of Family History on Detection of High-grade Prostate Cancer in a Large Multi-institutional Cohort

Clements, Matthew; Vertosick, Emily; Guerrios-Rivera, Lourdes; Hoedt, Amanda M. De; Hernández, Javier; Liss, Michael A.; Leach, Robin J.; Freedland, Stephen J.; Haese, Alexander; Montorsi, Francesco; Boorjian, Stephen A.; Poyet, Cédric; Ankerst, Donna P.

doi:10.1016/j.eururo.2021.12.011

Cited by 17 publications

(9 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We have not had detail information about the father's and brother's PCa aggressiveness; therefore, we could not have analyzed the correlation between paternal/son pairs and fraternal pairs' PCa aggressiveness. Although, Meissner et al demonstrated that a paternal fatal FH was associated with a better cancer-specific survival after RP among the fraternal, paternal, multiple, and none fatal FH groups, 29 and Clements et al demonstrated that the estimated odds of high-grade PCa were higher with two or more versus one first-degree relatives with PCa (odds ratio 1.92 vs. 1.54), 30 due to the very small number of patients with fraternal pairs and more than one FH in this study, we could not make any definitive conclusions. Since the frequency of first-degree breast, pancreas, and colorectal cancer in the FH group were much higher than that in the NFH group, further investigation is needed whether other family histories involve in PCa outcomes.…”

Section: Discussionmentioning

confidence: 99%

Impact of family history on clinicopathological variables and disease progression in Japanese prostate cancer patients undergoing robotic‐assisted radical prostatectomy

et al. 2022

View full text Add to dashboard Cite

Objective We evaluated whether a first‐degree family history (FH) of prostate cancer (PCa) in Japanese patients undergoing robotic‐assisted radical prostatectomy (RP) is correlated with clinicopathological variables and disease progression. Methods We reviewed consecutive 392 localized PCa patients undergoing robotic‐assisted RP at our institution between 2015 and 2020. Information on FH was obtained via a self‐administered questionnaire. A positive FH was defined as having a first‐degree FH: a father and/or one or more brothers with PCa prior to diagnosis. All patients had clinically localized PCa treated by robotic‐assisted RP. We evaluated the relationship between clinical characteristics, pathological findings, and biochemical progression‐free survival (bPFS) according to first‐degree FH status. Results Median follow‐up was 20.8 months. FH was identified in 42 (10.7%) patients. Patients in the FH group (median, 64.8 years) were diagnosed at a significantly younger age than patients in the non‐FH (NFH) group (patients without FH) (median, 67.7 years) (p = 0.003). The 5‐year bPFS in the FH and NFH groups was 72.0% and 78.1%, respectively (p = 0.90). A subgroup analysis revealed a significant difference in prostate‐specific antigen (PSA) density between the FH group (median, 0.51 ng/ml/cm3) and the NFH group (median, 0.29 ng/ml/cm3) in patients younger than 60 years (p = 0.033). Conclusions In this RP population, FH of PCa was not associated with worse clinical characteristics, pathological findings, or disease progression. Patients with a FH underwent surgery at a significantly younger age, and among patients <60 years, patients with a FH had significantly higher PSA density compared with patients without a FH.

show abstract

Section: Discussionmentioning

confidence: 99%

Impact of family history on clinicopathological variables and disease progression in Japanese prostate cancer patients undergoing robotic‐assisted radical prostatectomy

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Literature has shown that a history of PCa in a first-degree relative is associated with aggressive disease. 46 Likewise, a history of female breast cancer in firstdegree relatives was associated with an increased risk of PCa, often of a high grade. 47…”

Section: Risk Factors For Prostate Cancermentioning

confidence: 99%

The profile of Black South African men diagnosed with prostate cancer in the Free State, South Africa

Benedict

Steinberg

Claassen³

et al. 2023

S Afr Fam Pract

View full text Add to dashboard Cite

Background: Prostate cancer (PCa) ranks high in terms of morbidity and mortality, especially in Africa. Prostate-specific antigen (PSA) screening remains a practical method of screening for and thereby detecting PCa early, especially among African men who are more negatively affected. Modifiable risk factors for PCa are mostly behavioural and lifestyle. Understanding community-specific determinants is important when developing health promotion interventions.Objective: This study aimed to determine the profile of African men with PCa in the Free State, South Africa.Method: A cross-sectional descriptive study was conducted using case record information and self-administered questionnaires among 341 African men with PCa attending the oncology and urology clinics of a tertiary hospital.Result: Participants’ median age at diagnosis was 66 years. Only 76 (22.3%) participants had ever heard of PCa prior to being diagnosed with the disease, 36 (47.4%) of whom had ever had screening performed. The majority (n = 298, 87.4%) were symptomatic; 50% sought medical help within six months. At diagnosis, 133 (39.0%) men presented with stage T3 or T4 disease, 75 (22.0%) with metastatic disease and 84 (24.6%) with Gleason score ≥ 8. Factors associated with advanced and high-grade disease included smoking, decreased sunlight exposure and physical activity, relatively increased ingestion of dairy products and red meat. Factors associated with early stage and low-grade disease included relatively increased ingestion of fruits, vegetables and fish.Conclusion: Advanced and high-grade PCa disease is not uncommon among men ≥ 60 years in this study setting. Certain modifiable risk factors associated with advanced disease were established in this study. The majority had lower urinary tract symptoms (LUTS) prior to PCa diagnosis, but they were of poor health-seeking behaviour. Although there seems not to be a systematic delay in the definitive diagnosis and initiation of treatment for PCa, there is a need to improve on health education and awareness in the study setting.

show abstract

“…Studies have consistently found elevated risk of prostate cancer in patients with a family history of prostate cancer 20,21 and also in patients with a family history of prostate and breast cancer. 22,23 Patients with a strong family history (eg, 2 or more first-degree relatives) have a 4-fold relative risk compared to those without a family history 24 and should ideally be genotyped to ascertain whether this is associated with a pathogenic variant (eg, BRCA1/2 , Lynch syndrome, ATM , CHEK2 ) or 1 or more of a growing set of identified germline DNA damage-repair mutations found in patients with metastatic prostate cancer diagnoses.…”

Section: Guideline Statementsmentioning

confidence: 99%

Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening

et al. 2023

View full text Add to dashboard Cite

Purpose:The summary presented herein covers recommendations on the early detection of prostate cancer and provides a framework to facilitate clinical decision-making in the implementation of prostate cancer screening, biopsy, and follow-up. This is Part I of a two-part series that focuses on prostate cancer screening. Please refer to Part II for discussion of initial and repeat biopsies as well as biopsy technique.Materials and Methods:The systematic review utilized to inform this guideline was conducted by an independent methodological consultant. The systematic review was based on searches in Ovid MEDLINE and Embase and Cochrane Database of Systematic Reviews (January 1, 2000–November 21, 2022). Searches were supplemented by reviewing reference lists of relevant articles.Results:The Early Detection of Prostate Cancer Panel developed evidence- and consensus-based guideline statements to provide guidance in prostate cancer screening, initial and repeat biopsy, and biopsy technique.Conclusions:Prostate-specific antigen (PSA)-based prostate cancer screening in combination with shared decision-making (SDM) is recommended. Current data regarding risk from population-based cohorts provide a basis for longer screening intervals and tailored screening, and the use of available online risk calculators is encouraged.

show abstract

Defining the Impact of Family History on Detection of High-grade Prostate Cancer in a Large Multi-institutional Cohort

Cited by 17 publications

References 22 publications

Impact of family history on clinicopathological variables and disease progression in Japanese prostate cancer patients undergoing robotic‐assisted radical prostatectomy

Impact of family history on clinicopathological variables and disease progression in Japanese prostate cancer patients undergoing robotic‐assisted radical prostatectomy

The profile of Black South African men diagnosed with prostate cancer in the Free State, South Africa

Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening

Contact Info

Product

Resources

About